Steinbach William J, Stevens David A
Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University, Durham, North Carolina, USA.
Clin Infect Dis. 2003 Oct 1;37 Suppl 3:S157-87. doi: 10.1086/376523.
The incidence of invasive aspergillosis is markedly increasing, and mortality remains dismal. Previously there were only 2 antifungals with activity against Aspergillus, but over the last few years there has been an explosion of newer agents and reformulations of older antifungals. Exploration has also begun with immunotherapy, with use of cytokines and granulocyte transfusions alone or in combination with antifungal therapy. This review will detail the available in vitro, in vivo, and clinical experience with the newer antifungal and immunomodulatory therapies in development for treatment of invasive aspergillosis.
侵袭性曲霉病的发病率正在显著上升，死亡率仍然很高。以前只有两种抗真菌药物对曲霉菌有活性，但在过去几年中，新型药物和旧抗真菌药物的重新配方大量涌现。免疫疗法也已开始探索，单独使用细胞因子和粒细胞输注或与抗真菌治疗联合使用。本综述将详细介绍正在开发用于治疗侵袭性曲霉病的新型抗真菌和免疫调节疗法的现有体外、体内和临床经验。
